Moreover, the reduction in hemolysis was demonstrated to be independent of HU, and the increase in Hb levels was not associated with an increased number in VOCs.42 Despite the increase in Hb levels and the reduction in hemolysis, the VOC reduction was non-significant.41 For this reason, voxelotor may represent a therapeutic option in patients with hemolytic complications, such as severe anemia, more than in patients with frequent and severe VOCs. The gene discussed is GSTM1; the disease is anemia (phenotype).